• IntegraGen’s court hearing on a proposed asset sale ended with the case taken under advisement; a ruling is due Oct. 9, 2026.
• The court reviewed two takeover bids from ABL Diagnostics and Health In Code for selected activities and assets.
• Neither bid includes a purchase of IntegraGen shares; sale proceeds would go to creditors under insolvency rules.
• The process flags a risk of total loss for shareholders; a judicial liquidation would trigger delisting from Euronext Growth Paris.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IntegraGen SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261005129237) on October 05, 2026, and is solely responsible for the information contained therein.